Biomarkers of Unrecognized Physiological Stress in Primary Care

Abstract

Unrecognized physiological stress is a pervasive clinical challenge in primary care, often underlying diverse presentations and contributing to chronic disease morbidity. Biomarkers offer objective, quantifiable means to detect and monitor physiological stress, yet their clinical integration remains limited. This review synthesizes recent evidence on established and emerging biomarkers, discusses their mechanistic relevance, and evaluates practical implications for primary care physicians. Special attention is given to epidemiological trends, risk stratification, diagnostic utility, and evolving guideline recommendations.

Introduction

Physiological stress reflects a spectrum of adaptive and maladaptive responses to internal or external demands. In primary care, stress-related disorders frequently present with non-specific symptoms, complicating diagnosis and management. Traditional reliance on clinical history and subjective assessments may overlook unrecognized stress, underscoring the need for objective biomarkers. Recent advances in stress physiology and molecular diagnostics have expanded the repertoire of biomarkers suitable for primary care settings, yet translation to routine practice remains a work in progress. This article reviews the current landscape and clinical relevance of biomarkers for detecting unrecognized physiological stress.

Epidemiology / Disease Burden

Physiological stress is implicated in a wide array of medical conditions, including cardiovascular diseases, metabolic syndrome, psychiatric disorders, and immunological dysfunction. Epidemiological surveys report that up to 70% of primary care visits may have an underlying stress component, either as a primary or contributing factor. Unrecognized stress is associated with increased healthcare utilization, poorer clinical outcomes, and elevated risk of chronic disease progression. The World Health Organization recognizes stress as a significant global health issue, with indirect costs related to lost productivity and increased morbidity estimated in the hundreds of billions annually. Despite its prevalence, physiological stress often remains undetected in primary care, highlighting the need for robust screening tools.

Pathophysiology

Exposure to stressors activates the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system, resulting in the release of glucocorticoids (primarily cortisol), catecholamines (epinephrine and norepinephrine), and downstream inflammatory mediators. Chronic or maladaptive activation disrupts homeostasis, leading to neuroendocrine dysregulation, immune suppression, endothelial dysfunction, and metabolic alterations. These pathophysiological changes underpin the clinical sequelae of unrecognized stress and provide a rationale for biomarker-based detection. Key mechanistic biomarkers include serum and salivary cortisol, dehydroepiandrosterone sulfate (DHEA-S), heart rate variability (HRV), C-reactive protein (CRP), and pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α).

Risk Factors

Risk factors for unrecognized physiological stress are multifactorial and include personal, occupational, and environmental contributors. Individuals with chronic medical conditions, limited social support, high job demands, or exposure to psychosocial adversity are disproportionately affected. Certain populations—such as caregivers, frontline healthcare workers, and individuals with underlying psychiatric disorders—are at heightened risk. Genetic predisposition, lifestyle factors (e.g., sleep deprivation, poor nutrition, substance use), and comorbid conditions (diabetes, hypertension) further modulate stress vulnerability and biomarker profiles.

Clinical Features

Unrecognized physiological stress often manifests with subtle, non-specific symptoms, including fatigue, sleep disturbances, gastrointestinal complaints, palpitations, headaches, and mood changes. Overlap with somatic presentations of other chronic diseases complicates clinical recognition. In addition, stress-related physiological changes may exacerbate existing conditions, such as hypertension or diabetes, or contribute to treatment resistance. Physical examination is generally unremarkable, and symptom questionnaires may lack sensitivity for early or atypical presentations.

Diagnosis

Objective biomarkers serve as valuable adjuncts in the detection and monitoring of physiological stress. Serum and salivary cortisol remain the most extensively studied, offering insight into HPA axis function. DHEA-S provides complementary information on adrenal reserve and resilience. HRV, measurable via wearable devices, reflects autonomic regulation and has prognostic value in cardiovascular risk assessment. Inflammatory markers, including high-sensitivity CRP, IL-6, and TNF-α, reveal the systemic impact of chronic stress. Composite biomarker panels and emerging omics-based approaches (proteomics, metabolomics) are under investigation for improved diagnostic accuracy. Selection of specific biomarkers should be guided by clinical context, logistical feasibility, and interpretive expertise.

Treatment & Management

Management of physiological stress in primary care relies on a multimodal approach, integrating patient education, behavioral interventions, and pharmacotherapy when indicated. Cognitive-behavioral therapy (CBT), mindfulness-based stress reduction, and lifestyle modifications (sleep hygiene, physical activity, nutrition) form the cornerstone of non-pharmacological strategies. Biomarker-guided monitoring enables personalized interventions and facilitates early identification of treatment responders or non-responders. Pharmacological options, such as selective serotonin reuptake inhibitors (SSRIs) or anxiolytics, may be considered for refractory cases or concomitant psychiatric comorbidity, with close monitoring for adverse effects.

Recent Advances / Emerging Therapies

Recent research has expanded the repertoire of stress biomarkers, with advances in point-of-care testing and digital health technologies. Salivary and hair cortisol assays offer non-invasive, longitudinal assessment of HPA axis activity. Machine learning algorithms incorporating biomarker data and patient-reported outcomes are being developed for risk stratification and predictive modeling. Omics technologies—including transcriptomics, metabolomics, and epigenetic profiling—hold promise for identifying novel biomarkers and elucidating stress-related pathobiology. Integration of biomarker data with electronic health records and wearable sensor analytics is an area of active investigation, potentially transforming stress detection and management in primary care.

Guideline Recommendations

Current guidelines from professional bodies such as the American Academy of Family Physicians and the European Society of Cardiology endorse the use of validated screening tools for stress and related disorders in high-risk populations. While routine biomarker screening is not universally recommended, targeted testing may be appropriate in patients with unexplained symptoms, high-risk profiles, or inadequate response to standard interventions. Clinicians are advised to interpret biomarker results in the context of clinical findings and to integrate multidisciplinary care for optimal management. Ongoing guideline updates are anticipated as evidence for biomarker-based approaches accrues.

Conclusion

Biomarkers offer a promising avenue for the detection and management of unrecognized physiological stress in primary care, augmenting clinical assessment and enabling personalized care. While several biomarkers—including cortisol, HRV, and inflammatory mediators—are supported by robust evidence, barriers to widespread adoption persist, including logistical challenges, cost, and interpretive complexity. Ongoing research and advances in digital health are poised to enhance the utility and accessibility of biomarker-based stress assessment. Primary care physicians should remain informed of evolving evidence and integrate biomarker data judiciously to optimize patient outcomes.